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Introduction
The Human Papilloma Virus (HPV) is one of the most 
important oncogenic viruses for humans. Researches on 
its epidemiology, pathogenic mechanisms and preven-
tive tools had an acceleration since preventive HPV vac-
cines started their way towards approval by regulatory 
authorities. An impressive number of articles have been 
published in international journals in the last years, and 
the same can be said about presentations and posters at 
congresses, meetings and symposia. One of the most 
important yearly events where new research data are 
usually anticipated, is the International Papillomavirus 
Conference, whose 25th edition was held in Malmo, 
Sweden, on May 8-14, 2009.
We summarise here a few particularly interesting se-
lected studies presented at the Conference regarding 
Papillomavrus preventative vaccines.
Immune response after primary 
vaccination course: a comparative 
trial of two HPV prophylactic vaccines 
(Einstein et al.) [1] 
Excellent clinical protection has been demonstrated so 
far for the two available HPV vaccines by several clini-
cal trials and follow-up studies. 
This study aimed at comparing the antibody responses 
measured one month after the administration of a com-
plete course of vaccination either with the bivalent and 
the quadrivalent HPV vaccines. 
In an observer-blind study, women (n = 1,106) were 
stratified by age (18-26, 27-35, 36-45 years) and ran-
domized (1:1) to receive Cervarix™ (Months 0, 1, 6) 
or Gardasil® (Months 0, 2, 6). Antibody responses 
were evaluated in sera and in cervicovaginal secre-
tions [CVS] by pseudovirion-based neutralization assay 
(PBNA, developed by NCI) and ELISA, and memory 
B-cell responses (sera) by ELISPOT assay.
In the According-To-Protocol (ATP) cohort (seron-
egative/DNA-negative before vaccination for HPV type 
analyzed), Geometric Mean Titres (GMTs) of serum 
neutralizing antibodies measured by PBNA at Month 
7 were 2.3-4.8-fold higher for HPV-16 and 6.8-9.1-
fold higher for HPV-18 with Cervarix™ compared with 
Gardasil®, across all age strata. In the Total Vaccinated 
Cohort (TVC) (women who received ≥ 1 dose), Cervar-
ix™ induced significantly higher HPV-16 and -18 serum 
neutralizing antibody titers (p < 0.0001) for each antigen 
in each age stratum. Positivity rates for anti-HPV-16/18 
neutralizing antibodies in CVS and circulating HPV-
16/18-specific memory B-cell frequencies were higher 
for Cervarix™ compared with Gardasil®. Both vaccines 
were generally well tolerated. Rates of solicited symp-
toms were higher for Cervarix™, injection site reactions 
being most common. Compliance was high (84%) for 
both vaccines. 
Comment. This study shows a significantly higher 
antibody response to the L1 protein of HPV 16 and 
18 in women immunised with the bivalent compared 
to the quadrivalent vaccine. A higher titre of anti-L1 
antibodies at the end of the immunisation course is 
likely to mean their longer-term duration, according 
to the experience of decay of antibodies registered 
after other vaccinations (for instance, hepatitis B). 
Future studies will hopefully clarify the exact role 
of antibody titres and of immunological memory for 
long-term protection. The recall effect of viral chal-
lenge at the mucosal level might play a role, but 
whether natural exposure to HPV induces an anam-
nestic response to L1 protein in vaccinees remains to 
be demonstrated. At the same time, the mechanism 
of protection conferred by vaccination has not been 
completely elucidated. The most likely hypothesis is 
that antibodies pass through from blood to the cervi-
cal mucus (natural site of infection and lesion), where 
they would be able to neutralise vaccine-types HPV 
virions. The implications of the response to this ques-
tion are crucial to understand whether an elevated 
titre of anti-L1 is an obliged pre-requisite for long-
term protection, or if immunity can rely also on the 
anamnestic response of memory B cells to nascent 
infection.
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Long-term efficacy of a prophylactic 
human papillomavirus type 16 vaccine 
(Rowhani-Rahbar et al.) [2]
The first protptype vaccine, against HPV 16 (never 
available for commercial use) was administered in a 
clinical trial a mean of 8.5 years ago (range: 7.2-9.5 
years). This follow-up study was intended to evaluate 
the long-term efficacy of this precursor of the present 
quadrivalent vaccine (Gardasil®) in 290 women who 
had participated in a phase IIb randomised controlled 
trial (RCT) of this vaccine in Seattle (November 1998-
January 2004). During the RCT period, one woman 
exhibited HPV-16 infection by HPV DNA detection 
at a single visit (month 12) in the vaccine group; 15 
women exhibited HPV-16 infection and 5 women de-
veloped HPV-16-associated CIN in the placebo group. 
During the extended follow-up period, no woman 
exhibited HPV-16 infection or developed HPV-16-as-
sociated CIN in the vaccine group; 6 women exhibited 
HPV-16 infection (vaccine efficacy [VE] = 100%; 95% 
confidence interval [CI]: 25%-100%) and 3 women 
developed HPV-16-associated CIN (VE = 100%; 95% 
CI: < 0%-100%) in the placebo group. Approximately 
86.3% of vaccine recipients remained HPV-16 competi-
tive Luminex(R) immunoassay seropositive at 8.5 years. 
Overall,throughout the combined RCT and extended 
follow-up periods, 1 woman exhibited HPV-16 infec-
tion and no woman developed HPV-16-associated CIN 
in the vaccine group; 21 women exhibited HPV-16 in-
fection (VE = 96%; 95% CI: 73%-100%) and 8 women 
developed HPV-16-associated CIN (VE = 100%; 95% 
CI: 47%-100%) in the placebo group.
Comment. The virtual 100% efficacy of the monovalent 
vaccine against HPV type 16 is reassuring in view of 
the required long-term effectiveness vis-à-vis the long 
foreseen sexual life after administration of prophylactic 
vaccination at pre-adolescent age. However, it must 
be underlined that each vaccine formulation may have 
different characteristics also regarding the long-term 
effectiveness, and therefore long-term protection of the 
quadrivalent vaccine cannot be directly inferred from 
data of one of its precursors.
Final phase III efficacy analysis 
of Cervarix™ in young women 
(J Paavonen et al.) and Cross-protective 
efficacy of Cervarix™ against oncogenic 
HPV types beyond HPV-16/18
(R. Skinner et al.) [3, 4]
The former of these two studies (representing in reality 
two sub-sets of results of the same study) reports the 
data on the final outcome of the phase 3 clinical trial of 
the bivalent 16/18 AS04 adjuvanted vaccine (Cervarix™, 
GlaxoSmithKline), after the interim analysis published 
in The Lancet by the same Authors in 2007 [5].
The primary objective was to evaluate vaccine efficacy 
(VE) against HPV-16/18 CIN2+. Secondary and explora-
tory objectives included VE against CIN2+ associated 
with any oncogenic HPV types, CIN2+ overall (i.e., ir-
respective of HPV type detected in the lesion) and safety. 
The study population consisted of 18,644 women 15-25 
years (total vaccinated cohort; TVC), who received ei-
ther HPV-16/18 vaccine (n = 9,319) or a control vaccine 
(HAV) (n = 9,325) at Months 0, 1, 6. Cervical samples 
were collected every 6 months for HPV DNA typing; 
gynecological and cytopathological examinations were 
performed every 12 months. Efficacy analyses were per-
formed in the According-To-Protocol cohort for Efficacy, 
(i.e., those meeting all eligibility criteria, complying with 
the protocol procedures, without any protocol viola-
tions, who were given three vaccine doses, had normal 
or low-grade cytology at baseline, and were valuable for 
efficacy) (ATP-E; vaccine = 8,083; control = 8,069; mean 
[SD] follow-up: 34.9 [6.41] months after dose three), in 
the TVC and the TVC naive (a subset of the TVC that in-
cluded subjects who had normal or low-grade cytology at 
baseline, who received ≥1 vaccine dose, were seronega-
tive for HPV-16/18 and DNA negative for 14 oncogenic 
HPV types at baseline; vaccine = 5,822; control = 5,819). 
Safety was assessed in all valuable women. 
Vaccine efficacy (and relevant 96.1% confidence intervals 
-CI) against HPV-16/18 CIN2+ in the According-To-Pro-
tocol for Efficacy population was 92.9% (79.9;98.3) in the 
pre-defined primary analysis (defined as a positive HPV16 
or HPV18 result as detection of either type by SPF10-
LiPA25 system or by type-specific PCR in vaccinated 
and non vaccinated cohorts), and 98.1% (88.4;100) in an 
analysis that assigned probable HPV causality in lesions 
containing multiple HPV types; and was 98.4% (90.4; 100) 
in the TVC naive. Overall, VE against CIN2+ was 30.4% 
(16.4; 42.1) in the TVC (regardless of baseline cytological, 
serological and DNA status) and 70.2% (54.7; 80.9) in 
the TVC naive. Rates of adverse events (including serious 
adverse events and medically significant conditions) were 
generally similar between groups.
In the other presented subset of the study, the TVC-
naïve cohort of women was considered (Mean [SD] 
follow-up: 39.5 [8.99] months). Vaccine efficacy (VE) 
(96.1% CI; p-value) against CIN2+ was: 100% (82.2, 
100; p < 0.0001) for HPV-31 /45, 68.2% (40.5, 84.1; p < 
0.0001) for the 5 most frequent oncogenic types (HPV-
31 /33 /45 /52 /58), 68.4% (45.7, 82.4; p < 0.0001) for 
the 10 most frequent oncogenic types (HPV-31 /33 /35 
/39 /45 /51 /52 /56 /58 /59), 66.1% (37.3, 82.6; p < 
0.0001) for A9 species (HPV-31 /33 /35 /52 /58) and 
77.3% (36.0, 93.7; p = 0.0009) for A7 species (HPV-39 
/45 /59 /68). Cross-protection was further substantiated 
by VE against individual HPV types including 31, with 
92·0% VE (66.0 to 99.2; p < 0.0001) against CIN2+, 
and 45, for which statistically significant protection was 
demonstrated against 12-month persistent infection, VE 
63.0% (18.4, 84.7; p = 0.0049) [6]. Overall VE against 
CIN2+ associated with 14 oncogenic types, including 
vaccine types (HPV16 /18 /31 /33 /35 /39 /45 /51 /52 /56 
/58 /59 /66 /68) was 77.7% (63.5, 87.0; p < 0.0001).
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Comment. The final results of the phase III trial of the 
bivalent vaccine confirm the high protective efficacy of 
the vaccine against CIN2+ lesions due to HPV 16 /18. 
The 93% efficacy in the ATP-E population resulting 
from pre-specified criteria (designed irrespective of 
the high probability of multiple HPV types infection) is 
further improved (98%) when an algorythm is used to 
assign causality to one of different HPV types present 
in a lesion.
The overall results of efficacy against CIN2+ due to all 
HPV types in the Total Vaccinated Cohort Naive (about 
70%) are a proxy of the expected impact of vaccination 
on total CIN2+ lesions in the pre-adolescent cohorts, 
who are the main object of routine immunisation pro-
grammes. On the other hand, the about 30% efficacy 
against all CIN2+ lesions in the TVC cohort represent 
the potential impact of catch-up vaccination policies 
including sexually-active young women who might be 
immunised when already infected by HPV. 
Data on cross protection towards CIN2+ and persistent 
infection caused by vaccine-related HPV types represent 
another very important result, since they mean a poten-
tially further 10-15% preventable pre-cancerous lesions 
in addition to those caused by HPV 16 and 18. As a 
matter of fact, vaccine types 16 and 18, together with 
HPV 31, 33 and 45 (types for which cross-protection 
is particularly important and desirable, and that was 
demonstrated at variable level for the bivalent vaccine) 
cause altogether about 82% of all cervical cancers.
Rapid decline in warts after national 
quadrivalent HPV vaccine program 
(Fairley et al.) [7]
Since Australia was the first country to offer free of 
charge vaccination with HPV vaccine to several cohorts 
of girls (12-18 year old since April 2007) and to women 
(26 year old through general practices since July 2007), 
and due to the short incubation period between infec-
tion and manifestation of genital warts, that country 
represents the best place where to verify the impact of 
the HPV vaccine in the field following extended immu-
nisation programmes.
The aim of this study was to measure the proportion 
of new clients with genital warts at Melbourne Sexual 
Health Centre (MSHC) from January 2004 to Decem-
ber 2008. Thirty-six-thousand-fifty-five new clients 
attended MSHC between 2004-2008 and genital warts 
were diagnosed in 3,826 (10.6%; 95% confidence 
intervals (CI): 10.3-10.9). Clinical prevalence ratios 
(RR), and 95% CIs were calculated for the proportion 
of new clients with genital warts for 2004-2007 com-
bined compared to 2008. The proportion of new clients 
with genital warts was significantly lower in 2008 than 
2004-2007 for men (RR = 0.82 [95% CI, 0.75-0.90]) 
and women (RR = 0.62 [95% CI, 0.54-0.72]). Analysis 
of subgroups found only women <28 years (RR = 0.52 
[95% CI, 0.44-0.63]) and heterosexual men (RR = 0.83 
[95% CI, 0.74-0.92]) but not homosexual men (RR = 
0.93 [95% CI, 0.73-1.17]) or women ≥ 28 years (RR = 
0.91 [95% CI 0.70-1.17]) had a significant fall in genital 
warts in 2008 compared to 2004-2007. From January to 
December 2008 there was a significant decline in the 
monthly presentations for warts among women < 28 
years (p for trend = 0.03).
Comment. In spite of the clear limitations that every 
field evaluation performed in a relatively short time 
interval inevitably has, this study is suggestive of a 
marked impact of extended vaccination programmes 
on the incidence of genital warts among vaccinated 
women, and supports some benefit being conferred to 
men. A reduction in genital wart diagnoses in heterosex-
ual but not homosexual men is consistent with reduced 
heterosexual transmission of HPV as a result of female 
vaccination.
Quadrivalent HPV vaccine effficacy 
against male genital disease 
and infection (Giuliano et al.) [8]
Although HPV-related diseases undoubtedly exert their 
pathogenic potential mainly in women, however also 
men experience benign diseases (especially genital 
warts) and pre cancerous and cancerous lesions of the 
genital and anal area. This study examined the efficacy 
of the quadrivalent HPV L1 virus-like particle vaccine
against incidence of HPV 6/11/16/18-related external 
genital lesions (EGL) (external genital warts, penile/
perineal/perianal intraepithelial neoplasia, and penile/
perineal/perianal cancer) as well as genital HPV 6 /11 
/16 /18 infection in young men (heterosexual men and 
men having sex with men).
A cohort of 4,065 young men aged 16-26 years received 
quadrivalent HPV vaccine or placebo at enrollment, 
month 2, and month 6. Subjects underwent detailed 
genital exams as well as sampling from the penis, scro-
tum, and perineal/perianal region at enrollment, month 
7 and at 6-month intervals afterwards. After enrollment, 
all new lesions were biopsied for pathological diagnosis 
and PCR testing. Efficacy analyses were performed in 
a per-protocol population seronegative at day 1 and 
HPV DNA-negative from day 1 through month 7 to the 
relevant vaccine HPV type. Median follow-up was 2.3 
years (starting from month 7).
Among 1,397 vaccine subjects and 1,408 placebo 
subjects, efficacy against any HPV 6/11/16/18-related 
external genital lesion was 90.4% (95% CI: 69.2, 98.1). 
Vaccine efficacy against condyloma and PIN was 89.4% 
(95% CI: 65.5, 97.9) and 100% (95% CI: <0, 100), re-
spectively. Vaccine efficacy against HPV 6/11/16/18 
persistent infection and DNA detection at one or more 
visits was 85.6% (97.5% CI: 73.4, 92.9), and 44.7% 
(95% CI: 31.5, 55.6), respectively. Slightly more injec-
tion-site adverse experiences were seen among vaccine 
recipients.
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Comment. Although present vaccination programmes 
are limited to women in the vast majority of countries, 
it is not excluded that an enlargement of such pro-
grammes might be desirable in the future to male popu-
lations. This study provides evidence of the efficacy of 
the quadrivalent HPV vaccine against external genital 
lesions in young men, both hetrosexual and homosexual, 
thus representing useful data to this potential aim.
Conclusions
The studies on HPV vaccination presented at the 25th 
International Papillomavirus Conference in Malmo 
confirm the key role that vaccines have in the strug-
gle against one of the most impacting viral diseases on 
human health. An impressive amount of data confirm 
the excellent performance of available vaccines, whose 
safety and efficacy profile (also thanks to the unforeseen 
cross protection they provide) is significantly greater 
than the initial forecasts.
The main challenge now, in addition to the continuing 
development of new generation products, will be that of 
implementing functioning immunisation programmes, 
particularly needed in low-income countries, where 
the burden of HPV related diseases is very high also 
due to the difficulty in setting up effective screening 
programmes.
Strong commitment will be needed by industrialised 
countries both to offer protection to more cohorts of 
their citizens, but also to join efforts in order to provide 
vaccine doses, and to help countries most in need to 
build the infrastructures and the manpower capacity 
that will allow all the world population to benefit from 
an essential, life saving medical technology like HPV 
vaccination.
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